Lisata Therapeutics Q3 2026 Results: Net Loss of $6.79M, Loss Widens
Lisata Therapeutics reported a significant increase in total assets to $648.4 million following the acquisition of Marea, which added $292.9 million in intangible assets and $64.7 million in goodwill. The company recorded a net loss of $6.8 million for the third quarter of 2026, with research and development expenses increasing to $5.2 million as they advance their combined pipeline.
- Key figure
- Net loss $6.79M